🔎 Trials Near Me

Beranda › Limfoma Sel B Besar Difus › Arizona

Uji klinis Limfoma Sel B Besar Difus di Arizona

13 studi untuk Limfoma Sel B Besar Difus mencari peserta di lokasi di Arizona.

Kota di Arizona

Teks studi resmi (Bahasa Inggris)

A Dose-Escalation and Expansion Study of Tacabrutideg (BGB-16673) in Participants With B-Cell Malignancies

  • Honor Health Research Institute, Scottsdale
  • University of Arizona Cancer Center, Tucson
Menerima pesertaFase 1/2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Sep 2026 · NCT05006716

A Clinical Study of Zilovertamab Vedotin (MK-2140) Plus Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Polatuzumab Vedotin Plus R-CHP in People With Diffuse Large B-cell Lymphoma (DLBCL) (MK-2140-011/waveLINE-011)

  • Ironwood Cancer & Research Centers ( Site 0204), Chandler
  • Palo Verde Cancer Specialists ( Site 0105), Glendale
  • City of Hope - Phoenix ( Site 0202), Goodyear
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06890884

A Study of Zilovertamab Vedotin (MK-2140) in Combination With Standard of Care in Participants With Relapsed or Refractory Diffuse Large B-Cell Lymphoma (rrDLBCL) (MK-2140-003)

  • Palo Verde Hematology/ Oncology Center, Ltd. ( Site 0175), Glendale
Menerima pesertaFase 2/3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT05139017

A Study to Evaluate Zilovertamab Vedotin (MK-2140) Combination With Rituximab Plus Cyclophosphamide, Doxorubicin, and Prednisone (R-CHP) Versus Rituximab Plus Cyclophosphamide, Doxorubicin, Vincristine, and Prednisone (R-CHOP) in Participants With Previously Untreated DLBCL (MK-2140-010)

  • Banner MD Anderson Cancer Center ( Site 0165), Gilbert
  • Banner MD Anderson Cancer Center - University Medical Center Phoenix ( Site 0167), Phoenix
  • The University of Arizona Cancer Center - North Campus ( Site 0124), Tucson
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 25 Sep 2026 · NCT06717347

A Study of LY4584180 in Adult Participants With Previously Treated Blood Cancers

  • Mayo Clinic - Scottsdale, Scottsdale
Menerima pesertaFase 1
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 22 Sep 2026 · NCT07226843

Consolidation of First-Line MRD+ Remission With Cema-cel in Patients With LBCL

  • Banner MD Anderson Cancer Center, Gilbert
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 31 Agu 2026 · NCT06500273

Lentiviral Gene Therapy (Zamtocabtagene Autoleucel) LTFU

  • Banner MD Anderson Cancer Center, Gilbert
Menerima pesertaStudi observasional
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 5 Agu 2026 · NCT06116110

A Study to Investigate Ronde-cel Versus Investigator's Choice CD19 CAR T-Cell Therapy

  • Banner MD Anderson Cancer Center, Gilbert
  • Honor Health, Scottsdale
  • Mayo Clinic Arizona, Scottsdale
Menerima pesertaFase 3
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 4 Agu 2026 · NCT07188558

DALY II USA/ MB-CART2019.1 for DLBCL

  • Banner MD Anderson Cancer Center, Gilbert
  • Mayo Clinic, Phoenix
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 13 Jul 2026 · NCT04792489

Testing Drug Treatments After CAR T-cell Therapy in Patients With Relapsed/Refractory Diffuse Large B-cell Lymphoma

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 2 Feb 2026 · NCT05633615

Golcadomide and Rituximab as Bridging Therapy for Relapsed or Refractory Aggressive B-cell Non-Hodgkin Lymphoma Before CAR T-cell Therapy

  • Mayo Clinic in Arizona, Scottsdale
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 28 Jan 2026 · NCT06834373

Study Adding Drugs to Usual Treatment for Large B-Cell Lymphoma That Returned or Did Not Respond to Treatment

  • Banner University Medical Center - Tucson, Tucson
  • University of Arizona Cancer Center-North Campus, Tucson
Menerima pesertaFase 2
Usia 18 ke atas · Semua jenis kelamin · Diperbarui 20 Okt 2025 · NCT05890352

Dari ClinicalTrials.gov, data diambil 2 Okt 2026. Setiap studi menetapkan kriteria kelayakannya sendiri; tim studi yang menentukan siapa yang bisa bergabung.